Stockscreener 앱 받기
3.62
2.69%
-0.10
시간 외 거래:
3.70
0.08
+2.21%
전일 마감가:
$3.72
열려 있는:
$3.75
하루 거래량:
35,052
Relative Volume:
0.10
시가총액:
$15.07M
수익:
-
순이익/손실:
$-33.44M
주가수익비율:
-0.2259
EPS:
-16.0242
순현금흐름:
$-28.30M
1주 성능:
-12.56%
1개월 성능:
+6.16%
6개월 성능:
-84.25%
1년 성능:
-98.57%
1일 변동 폭
$3.62
$3.8159
1주일 범위
$3.62
$4.55
52주 변동 폭
$2.78
$330.00
Nucana Plc Adr Stock (NCNA) Company Profile
NCNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NCNA
Nucana Plc Adr
|
3.62 | 15.48M | 0 | -33.44M | -28.30M | -16.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nucana Plc Adr Stock (NCNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-03 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-10-22 | 개시 | Truist | Buy |
| 2020-07-24 | 개시 | Oppenheimer | Outperform |
| 2019-08-19 | 개시 | H.C. Wainwright | Buy |
| 2018-10-19 | 개시 | Piper Jaffray | Overweight |
| 2017-10-23 | 개시 | Citigroup | Buy |
| 2017-10-23 | 개시 | Jefferies | Buy |
| 2017-10-23 | 개시 | William Blair | Outperform |
모두보기
Nucana Plc Adr 주식(NCNA)의 최신 뉴스
NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma - GlobeNewswire Inc.
NuCana stock rises after securing key patent in China for cancer drug - Investing.com
China grants key patent for NuCana’s cancer drug NUC-7738 - Investing.com
Taking the lead: NuCana plc ADR (NCNA) - Setenews
NuCana compliant with all Nasdaq continued listing criteria - MSN
Rising Momentum in European ADRs: A Strategic Entry Point for US Investors - AInvest
NuCana regains Nasdaq compliance, extends cash runway into 2029 - Investing.com
What recovery options are there for NuCana plc Depositary ReceiptJuly 2025 Update & Expert Curated Trade Ideas - Newser
How institutional ownership impacts NuCana plc Depositary Receipt stockWeekly Trade Recap & Accurate Trade Setup Notifications - Newser
Wall Street Today: Dow, Nasdaq, S&P 500 open flat as investors focus on China tariff deadline; Nvidia down 1.3% - Mint
NuCana plc ADR’s Shares Reel: -92.65% Quarterly Revenue Decline Amid 14.58M Market Cap - investchronicle.com
HEPS’s Stock Dilemma: D-MARKET Electronic Services & Trading ADR’s Market Performance and Outlook - investchronicle.com
NuCana plc Announces Change in American Depository Shares Ratio to Enhance Liquidity and Nasdaq Compliance - Quiver Quantitative
GIBO Holdings Ltd (NASDAQ: GIBO): Down -99.40% In 2025, Outlook Remains Negative - stocksregister.com
What is the dividend policy of NuCana plc Depositary Receipt stockTremendous gains - jammulinksnews.com
NuCana Stock Set to Reverse Split on Friday, August 8th (NASDAQ:NCNA) - Defense World
NuCana Cancels Series A Warrants Post-ATM Execution - The Globe and Mail
NuCana completes cancellation of all remaining Series A Warrants - Investing.com
NCNA’s Market Whiplash: -98.30% YTD Decline, -65.02% Plunge in 30 Days - investchronicle.com
NuCana Announces ADS Ratio Change to Enhance Liquidity - theglobeandmail.com
NuCana (NCNA) Announces 1-for-200 Reverse ADS Split Effective Aug 8 2025 - Stock Titan
NuCana to implement 1:200 reverse ADS split to boost share price - Investing.com
Nucana Plc shares surge 45% in premarket after receiving Nasdaq delisting notice and strong industry performance. - AInvest
NuCana (NCNA) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
NCNA Gets Second Nasdaq Notice; Hearing to Delay Potential Delisting - Stock Titan
NuCana enters $100 million at-the-market sales agreement for ADS offering - Investing.com
NuCana CEO takes leave of absence due to health reasons - Investing.com
nucana plc announces annual report release and upcoming agm - Investing.com India
NuCana's Melanoma Breakthrough: Key Drug Advances to Expansion Trial, Q1 Losses Drop 63% Year-over-Year - Stock Titan
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Benzinga
NuCana prices $7 million direct offering of ADSs and warrants - Investing.com
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season? - Nasdaq
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks - Yahoo Finance
NuCana secures new US patent for cancer treatment NUC-7738 - Investing.com
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance
NCNANuCana plc ADR Earnings - Finviz
NuCana stock downgraded by William Blair after halted cancer study - Investing.com
Nucana Plc Share Price (NCNA.US) - London South East
NuCana shares receive $150 stock PT at Oppenheimer on upbeat trial prospects - Investing.com
NuCana (NCNA) Stock Trends and Sentiment 2025 - MarketBeat
NuCana (NCNA) Stock Forecast and Price Target 2025 - MarketBeat
NuCana regains Nasdaq compliance with bid price rule - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
NuCana plcADR (NCNA) Price Target Increased by 15.39% to 5.10 - Nasdaq
NuCana plc (NCNA) Stock Forecast & Price Prediction 2025–2030 - CoinCodex
NuCana plc Sponsored ADR Earnings and Revenue – NASDAQ:NCNA - TradingView
Here's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks - Yahoo Finance
Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA) - Yahoo Finance
What is the current Price Target and Forecast for NuCana (NCNA) - Zacks Investment Research
Here's What NuCana plc's (NASDAQ:NCNA) Shareholder Ownership Structure Looks Like - Yahoo Finance
Nucana Plc ADR (NCNA-Q) Insider Trade Summaries - The Globe and Mail
Nucana Plc Adr (NCNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):